Landos Biopharma, Inc.
LABP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LABP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2024.
Tracking 2 pipeline candidates for Landos Biopharma, Inc..
Run Landos Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Landos Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
10.3 months
D/E 0.29 · 99% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is Landos Biopharma, Inc.'s lead drug candidate?
Landos Biopharma, Inc.'s most advanced tracked candidate is labp-69 (Preclinical) for Diabetic nephropathy and rheumatoid arthritis (RA).
Who is the CEO of Landos Biopharma, Inc.?
Tim M. Mayleben is the chief executive officer of Landos Biopharma, Inc. (LABP).
What therapeutic areas does Landos Biopharma, Inc. focus on?
Landos Biopharma, Inc. develops therapies across Neurology, Immunology, Metabolic, Respiratory, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.